The Expression of Matix Metalloproteinase-3 and Tissue Inhibitor of Metalloproteinase-1 in Ectopic Endometriosis

In: Hebei yixue · 2006 · W2347929221
OA: closed CC0
View on OpenAlex
⚙ AI-generated summary by qwen3.7-flash, 2026-10-15 ⓘ

This study found that elevated MMP-3 and reduced TIMP-1 expression in ectopic endometriosis tissues creates a higher MMP-3/TIMP-1 ratio, contributing to the enhanced invasive ability of endometrial implants.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Objective : To observe the expression of matrix metalloproteinase-3 (MMP-3) and tissue inhibitor of matrix metalloproteinase-1(TIMP-1) in endometriosis(EMs),and to study the possible roles of MMP-3 and TIMP-1 in the pathogenesis of EMs.Method: Immunohistochemical method was employed to detect the expression of MMP3 and TIMP-1 in ectopic endometrium(40 cases) and ectopic endometrium(42 cases) from women with EMs and normal endometrium(38 cases).Result: The levels of MMP-3 in ectopic endometrium tissues of EMs were significantly higher than those in the ectopic and normal endometrium(P 0.01).The expression of TIMP-1 in ectopic and eutopic endometrium of EMs was lower than that in the normal endometrium.There was significant difference in the positive expression ratio between them(P 0.01).Conclusion: The high expression of MMP-3 in EMs and lower expression of TIMP-1 in EMs resulting the higher ratio of MMP-3/TIMP-1 can contribute to the ectopic endometrium having stronger invasive ability than the normal endometrium.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK